An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
IO therapy resistant or insensitive tumors
Have at least 2 tumor lesions accessible for biopsy
Eastern Cooperative Oncology Group Performance Status of 0 or 1
You may not be if
Primary CNS malignancy
Participants with other active malignancy requiring concurrent intervention
Uncontrolled or significant cardiovascular disease
Clareo Health | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
